AZD6765 for Treatment Resistant Depression | NCT00491686 | Trialant

AZD6765 for Treatment Resistant Depression | NCT00491686 | Trialant

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
The primary objective is to determine whether an antidepressant effect can be achieved in patients with Treatment Resistant Depression determined by a change from baseline in the MADRS total score.		Change from Baseline

Secondary Outcomes

Measure	Description	Time Frame
The secondary objective is to assess the safety and tolerability of AZD6765 as assessed by vital signs, physical examination, clinical laboratory evaluations, ECG's and incidence of adverse events.		each visit; change from baseline

Contacts/Locations Module

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
34510411	Derived	Dean RL, Hurducas C, Hawton K, Spyridi S, Cowen PJ, Hollingsworth S, Marquardt T, Barnes A, Smith R, McShane R, Turner EH, Cipriani A. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612. doi: 10.1002/14651858.CD011612.pub3.
24126931